Events

Speaker:
Carlo Russo, M.D., CMO & Head of Development

Webcasting information: Fireside chats will be webcasted via Open Exchange. Additional details will be provided closer to the conference.

Speaker:
Pierluigi Paracchi, CEO and Co-founder
Carlo Russo, Chief Medical Officer & Head of Development

Tuesday May 17, 2:30-3:30 p.m. CET
West-East Roundtable: The Clinical Pathway to Europe-China Collaborations

Session Chair & Panelists:

• Joshua Berlin, Head of Business Development, BioCentury Inc. (Session Chair)
• Georg Büchner, Ph.D., Group Chief Business Officer, Helsinn Group
• James Huang, Founding Managing Partner, Panacea Healthcare Venture; Managing Partner, KPCB China 
• Stefania Mazzoleni Ph.D., Scientific Project Manager & Communication Officer, Genenta Science S.p.A
• Steven Powell, Ph.D., CEO, eTheRNA immunotherapies N.V.
• Debra Yu, M.D., President & Chief Strategy Officer, LianBio
• Guo-Liang Yu, Ph.D., Chairman, BayHelix; Co-Founder, Chairman & CEO, Apollomics Inc.

In person event  Venues 133 Houndsditch in London.
Go West! – Considerations For US IPOs And Dual Listings 

Moderator: Isabella Schidrich, Senior Managing Director, Nasdaq
Pierluigi Paracchi, CEO & Co-founder, Genenta Science
Steve Hurly, CEO, Lava Therapeutics
Piers Morgan, CFO, Cellcentric
Fredrik Johansson, CFO, Calliditas Therapeutics

Genenta Science speaker Pierluigi Paracchi CEO and co-founder

Here is the event agenda with list of speakers.

(https://www.linkedin.com/events/6886547189175197696).

LCA – in collaboration with Goodwin – will host the webinar “The NASDAQ IPO Path for Italian Life Science Companies: Genenta Science’s Case Study”, Speaker: Ettore Santucci (Goodwin), Pierluigi Paracchi (Genenta), Aparna Beeram (Roth Capital Partners), Federica Draghi (Genextra) and Leonardo Vingiani (Federchimica), together with Andrea Messuti (LCA)

Co-hosted by Nobel laureate and Biogen/Alnylam co-founder Phil Sharp.

CROSS-BORDER COLLABORATION
Stewart Geary, CMO, Eisai
Francesco Hofmann, Head, R&D, Pierre Fabre
Cristin Hubbard, Head, Global Partnering, Diagnostics, Roche
Ryan Richardson, Chief Strategy Officer, BioNTech
Carlo Russo, CMO, Genenta Science
Moderator: Stuart Mackey, Global Head, BD, Daiichi Sankyo

Hosted by Genenta Science
Moderated by Brad Loncar

In this fireside chat, Genenta is delighted to bring together renowned neuro-oncologist David Reardon, MD (Harvard Medical School, Dana-Farber Cancer Institute) and Professor Luigi Naldini, MD, PhD (San Raffaele Telethon Institute for Gene Therapy), considered by many as the “father” of lentiviral gene therapy to discuss the potential application of immuno gene & cell therapy as a potential treatment for glioblastoma and other solid tumors. Genenta's Temferon™, a lentivirus based hematopoietic stem progenitor cell immuno gene & cell therapy enabling controlled and targeted interferon-α expression within cancers, will be discussed as a potential treatment solution for glioblastoma patients.

Brad Loncar (CEO of Loncar Investments) will serve as the fireside chat moderator and Carlo Russo, MD (Genenta CMO & Head of Development) will also participate in the discussion.

A live question and answer session will follow.

Speaker: Stefania Mazzolone Ph.D Scientifica Project Manager and Communication Officier

The workshop will be held both in presence (by invitation only) and online In person event at MIND – Milan Innovation District